Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Zentalis Pharmaceuticals (ZNTL) Insider Trading & Ownership

Zentalis Pharmaceuticals logo
$1.69 -0.07 (-3.98%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 +0.01 (+0.30%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.90%
Number Of
Insiders Buying
(Last 12 Months)
3
Amount Of
Insider Buying
(Last 12 Months)
$178.20K
Number Of
Insiders Selling
(Last 12 Months)
2
Amount Of
Insider Selling
(Last 12 Months)
$23.33K
Get ZNTL Insider Trade Alerts

Want to know when executives and insiders are buying or selling Zentalis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZNTL Insider Buying and Selling by Quarter

Zentalis Pharmaceuticals Insider and Congressional Trades History

Export to Excel
Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/30/2025Scott Dunseth MyersDirectorBuy21,000$1.40$29,400.00  
2/6/2025Ingmar BrunsInsiderBuy20,000$2.28$45,600.00  
2/3/2025Vincent VultaggioInsiderSell2,615$1.71$4,471.65  
1/31/2025Jan SkvarkaDirectorBuy60,000$1.72$103,200.00  
1/2/2025Mark LacknerInsiderSell4,411$3.12$13,762.32  
10/4/2024Vincent VultaggioInsiderSell1,603$3.18$5,097.54  
(Data available from 1/1/2013 forward)

ZNTL Insider Trading Activity - Frequently Asked Questions

The list of insiders at Zentalis Pharmaceuticals includes Cam Gallagher, Carrie Brownstein, David Michael Johnson, Diana Hausman, Ingmar Bruns, Jan Skvarka, Kevin D Bunker, Kimberly Blackwell, Mark Lackner, Matrix Capital Management Comp, Melissa B Epperly, Scott Dunseth Myers, and Vincent Vultaggio. Learn more on insiders at ZNTL.

1.90% of Zentalis Pharmaceuticals stock is owned by insiders. Learn more on ZNTL's insider holdings.

The following insiders have purchased ZNTL shares in the last 24 months: David Michael Johnson ($167,960.00), Ingmar Bruns ($45,600.00), Jan Skvarka ($103,200.00), Kimberly Blackwell ($51,450.00), and Scott Dunseth Myers ($29,400.00).

Insiders have purchased a total of 123,000 ZNTL shares in the last 24 months for a total of $397,610.00 bought.

The following insiders have sold ZNTL shares in the last 24 months: Cam Gallagher ($128,391.18), Carrie Brownstein ($207,246.00), Diana Hausman ($42,352.72), Jan Skvarka ($125,250.00), Mark Lackner ($13,762.32), Melissa B Epperly ($136,334.12), and Vincent Vultaggio ($9,569.19).

Insiders have sold a total of 46,438 Zentalis Pharmaceuticals shares in the last 24 months for a total of $662,905.53 sold.

Zentalis Pharmaceuticals Key Executives

  • Dr. Kimberly Lynn Blackwell M.D. (Age 55)
    CEO & Director
    Compensation: $1.17M
  • Mr. Cameron S. Gallagher M.B.A. (Age 54)
    Co-Founder, President, Interim CFO, Interim Treasurer & Director
    Compensation: $892.15k
  • Ms. Andrea Paul J.D. (Age 43)
    Chief Legal Officer & Corporate Secretary
    Compensation: $682.47k
  • Dr. Diana F. Hausman M.D. (Age 61)
    Chief Medical Officer & Director
    Compensation: $38.44k
  • Mr. Vincent Vultaggio (Age 41)
    VP of Finance & Interim Principal Accounting Officer
  • Dr. Mark Lackner Ph.D. (Age 56)
    Chief Scientific Officer
  • Ms. Kimberly Freeman
    Chief Strategy Officer
  • Dr. Kyle Rasbach Ph.D. (Age 44)
    Pharm.D., Chief Business Officer
  • Dr. Adrian Jubb M.D.
    Ph.D., Executive Vice President of Clinical Development

Related Companies
Insider Tracking Tools
Insider Trading By Country
Latest Articles

This page (NASDAQ:ZNTL) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsoredtc pixel
Generate up to $5,000/month with 10X less money?
The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...
Investors Alley | Sponsoredtc pixel
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsoredtc pixel